Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.
According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.
Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.
Related Articles
Sichuan Biokin Pharmaceutical (688506.SH): T-Bren included in the breakthrough therapy designation list
Sichuan Biokin Pharmaceutical (688506.SH): BL-M05D1 for Injection Included in the Breakthrough Therapy Designation List
Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved
Sichuan Biokin Pharmaceutical (688506.SH): T-Bren included in the breakthrough therapy designation list
Sichuan Biokin Pharmaceutical (688506.SH): BL-M05D1 for Injection Included in the Breakthrough Therapy Designation List
Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of BL-M12D1 for injection (ADC) approved
